Hosted on MSN

AN2 Therapeutics stock jumps 90% Monday: What's driving the action?

AN2 Therapeutics Inc ANTX shares are surging Monday afternoon after the clinical-stage biopharmaceutical company announced a $40 million private placement financing. Here’s what investors need to know ...
Morningstar

AN2 Therapeutics Announces Plans to Advance Oral Epetraborole into Phase 2 Study for Polycythemia Vera (PV)

AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company developing novel small molecule therapeutics derived from its boron chemistry platform, today announced its plans to ...
Investing

AN2 Therapeutics enters $80 million at-the-market sales agreement with Jefferies

Additionally, AN2 Therapeutics plans to start another Phase 2 study focusing on epetraborole for adults with phlebotomy-dependent polycythemia vera. In financial developments, AN2 Therapeutics has ...
Seeking Alpha

AN2 Therapeutics Reports Data from the Phase 3 Portion of Previously Terminated EBO-301 Study and Outlines Future Milestones from Boron Chemistry Pipeline

EBO-301 truncated Phase 3 study (n=97) misses primary endpoint; results unable to confirm clinical efficacy observed in Phase 2 study, patients had underlying severe, advanced MAC lung disease ...
Seeking Alpha

AN2 Therapeutics Reports First Quarter 2025 Financial Results and Recent Business and Scientific Highlights

Cash, cash equivalents, and investments of $78.5 million at March 31, 2025 and cash runway anticipated to fund operations into 2028 MENLO PARK, Calif.--(BUSINESS WIRE)-- AN2 Therapeutics, Inc. (ANTX), ...